| Similar Articles |
|---|
 |
Chemistry World
March 20, 2008
Richard Van Noorden |
UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.   |
Pharmaceutical Executive
January 1, 2013
William Looney |
The Permanent Campaign Promoting the merits of private-sector drug innovation is no easy task; just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace. |
Chemistry World
September 5, 2014
Emma Stoye |
Servier to appear in adverts over lack of transparency European pharma group Servier Laboratories is to appear in adverts for breaching the Association of the British Pharma Industry code of practice by failing to publish clinical trial results. |
Pharmaceutical Executive
December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
Chemistry World
March 22, 2012
Andrew Turley |
GSK to build 350 million factory in UK GlaxoSmithKline has announced plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria. |
Fast Company
Christina Farr |
AHA, Alphabet Set Aside $75 Million To Cure Coronary Heart Disease The American Heart Association, Verily (the company formerly known as Google Life Sciences), and European pharmaceutical giant AstraZeneca are investing the funds over a five-year period. |
Bio-IT World
April 2007
Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
Chemistry World
March 4, 2013
Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries. |
Chemistry World
June 11, 2008
James Mitchell Crow |
GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
The Motley Fool
October 13, 2006
Rich Duprey |
NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost. |
Pharmaceutical Executive
May 1, 2007 |
Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge. |
Pharmaceutical Executive
December 1, 2006
Sarah Houlton |
Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
Pharmaceutical Executive
June 1, 2009
Patrick Clinton |
High School Justice FDA slaps down Cheerios and forces pharma companies that use Google to make technical changes no consumer will ever notice. Big whoop. |
Pharmaceutical Executive
February 1, 2007
Sarah Houlton |
Global Report: Under One Roof The UK government is planning to set up a single body to oversee all health research in universities and hospitals - and to facilitate partnerships between government agencies and industry. |
Chemistry World
September 7, 2015 |
Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs. |
The Motley Fool
March 26, 2009
Brian Orelli |
Big Pharma's R&D Model Is Broken Bigger isn't always better. |
The Motley Fool
April 19, 2006
Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge. |
Chemistry World
December 8, 2011
Sarah Houlton |
Academia Grows Its Role in Drug Discovery The number of pharma patents being filed by universities around the world is soaring compared with those coming from industry. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool
September 2, 2005
Rich Duprey |
An Opportunity Not to Forget Japanese pharmaceutical Eisai targets another segment of the growing Alzheimer's market. Investors, take note. |
Pharmaceutical Executive
August 1, 2008
Sarah Houlton |
Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared. |
Chemistry World
January 3, 2013
Sarah Houlton |
2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Chemistry World
March 16, 2007 |
Testing Times for 'Mega-Pharma' A stern warning and gloomy forecast were delivered to the pharmaceutical industry at the Drug Discovery and Technology Summit in London. |
Chemistry World
December 22, 2011
Sarah Houlton |
Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition. |
Pharmaceutical Executive
June 1, 2006
Patrick Clinton |
From the Editor: Forecast -- and Fast The glory of the years to come will be in new science, new medicines, and new cures. But someone has to do the hard, scary work of guaranteeing the survival of the businesses that bring new cures to patients. |
Chemistry World
May 28, 2008
Mark Peplow |
Cancer research gets collaborative funding boost In an effort to crack some of the biggest problems in cancer drug discovery, Cancer Research UK has launched a unique funding program that promises to help bridge the gap between fundamental research and big pharma pipelines. |
Pharmaceutical Executive
April 1, 2007
Sarah Houlton |
Global Report: If It Ain't Broke Under the UK's pricing scheme, drug prices have dropped by 21% in 10 years. Is it really time for a change? |
The Motley Fool
September 16, 2008
Brian Orelli |
Is Pharma Still a Safe Investment? People still have to take their medicine. Health care, like food, is something that just isn't very discretionary. And that bodes well for drugmakers. Really. |
Bio-IT World
November 14, 2003
Kathy Ordonez |
Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines. |
Pharmaceutical Executive
April 1, 2007 |
Thoughtleader: Melissa Brown, Center for Value-Based Medicine Here, co-author Melissa Brown discusses her book Evidence-Based to Value-Based Medicine and what's driving the move toward value-based medicine, how it will affect pharma, and why executives should embrace it. |
Pharmaceutical Executive
May 1, 2011
Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance. |
Chemistry World
May 4, 2006
Katharine Sanderson |
Cancer Charity Takes on Shelved Drugs Cancer Research UK, and its commercial arm, Cancer Research Technology have launched a clinical development partnership scheme to sweep up drug candidates that pharmaceuticals companies have deprioritized for not showing enough commercial promise. |
The Motley Fool
September 10, 2008
Brian Orelli |
Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
Chemistry World
July 3, 2014
Maria Burke |
Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
Chemistry World
November 21, 2008
Pete Mitchell |
UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry. |
The Motley Fool
October 30, 2007
Brian Orelli |
Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note. |
Chemistry World
September 11, 2014
Emma Stoye |
Pharma sales 'will reach $1 trillion' in 2014 Global sales in the pharmaceutical industry are set to go over the $1 trillion mark this year, according to a report by Thomson Reuters. |
Pharmaceutical Executive
December 1, 2008
Patrick Clinton |
Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Pharmaceutical Executive
August 1, 2006
Patrick Clinton |
From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible. |
Pharmaceutical Executive
September 1, 2008 |
Considering Consumer Change: Q&A with Jim Joseph, Saatchi & Saatchi How will pharma fare in the new age of health and wellness marketing? |
BusinessWeek
January 8, 2007
Catherine Arnst |
Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure. |
The Motley Fool
April 25, 2006
Brian Gorman |
Pharma Plays With Fire Drugmakers' short-term gain could lead to long-term pain. |
